Infinium Pharmachem P/B Ratio
Current P/B Ratio
2.63
Moderate Valuation
High - Premium to book value, growth expectations or asset-light model
Infinium Pharmachem (INFINIUM) P/B ratio is 2.63 (Moderate), book value per share ₹75.62 vs Healthcare average P/B of -0.31 — High - Premium to book value, growth expectations or asset-light model. View INFINIUM 52-week chart for the annual high/low range and current price position.
Current Valuation Metrics
P/B Ratio
2.63
Current Price
₹
Book Value/Share
₹75.62
Exchange
None
Book Value Breakdown (2026)
Balance Sheet Components
Total Equity
₹121 Cr
Share Capital
₹16 Cr
Reserves & Surplus
₹106 Cr
Outstanding Shares
16,000,000
Book Value per Share
₹75.62
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
-0.31
Sector Median
0.6
Sector Rank
#11 of 50
Sector Percentile
22.0%
INFINIUM P/B Ratio — Valuation Insights & Book Value Analysis
Infinium Pharmachem price-to-book ratio interpretation, valuation status and historical context — current P/B 2.63 (Moderate). Review Infinium Pharmachem price earnings to evaluate earnings-based valuation against sector peers.
- Trading at premium to sector average PB of -0.31
INFINIUM vs Healthcare Peers — P/B Ratio Comparison
Infinium Pharmachem P/B 2.63 vs Healthcare average -0.31, median 0.6 — range -16.4–1.11.
Sector Average
-0.31
Sector Median
0.6
Lowest P/B
-16.4
Highest P/B
1.11
Companies
50
| Company | Symbol | P/B Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Rekvina Laboratories | VINRKLB | -16.4 | ₹20 | Low |
| Span Divergent | SDL | -6.32 | ₹19 | Low |
| Oxygenta Pharmaceutical | OXYGENTAPH | -5.54 | ₹203 | Low |
| Parmax Pharma | PARMAX | -4.61 | ₹32 | Low |
| Satiate Agri | SATAGRI | -3.39 | ₹8 | Low |
| Adline Chem Lab | ADLINE | -3.03 | ₹5 | Low |
| Bharat Immunologicals | BIBCL | -2.23 | ₹73 | Low |
| Krebs Biochemicals & Ind… | KREBSBIO | -0.79 | ₹126 | Low |
| Cresanto Global | CRESANTO | -0.7 | ₹2 | Low |
| Vivimed Labs | VIVIMEDLAB | -0.56 | ₹47 | Low |